Literature DB >> 20606434

CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy.

Thomas P Baumann1, Hüseyin Duyar, Marc Sollberger, Jens Kuhle, Axel Regeniter, Baltazar Gomez-Mancilla, Klaus Schmidtke, Andreas U Monsch.   

Abstract

OBJECTIVE: Our purpose was to measure Abeta(1-42), T-tau and P-tau(181) in the cerebrospinal fluid (CSF) of patients with posterior cortical atrophy (PCA), a presenile dementia likely to represent a variant of Alzheimer's disease (AD).
METHODS: CSF samples from 34 subjects including 9 patients with PCA, 11 age-matched patients with AD and 14 age-matched cognitively healthy controls were analyzed using commercially available ELISA kits.
RESULTS: The Abeta(1-42), T-tau and P-tau(181) levels in PCA patients differed significantly (p < 0.02) from those in healthy controls but were indistinguishable from subjects with a clinical diagnosis of AD.
CONCLUSION: High T-tau and P-tau(181) and low Abeta(1-42) levels in PCA - typically observed in AD - indicate that the underlying pathology of PCA is usually AD. If these findings are replicated in PCA patients with autopsy-confirmed AD neuropathology, PCA patients may be eligible for disease-modifying AD treatments. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20606434     DOI: 10.1159/000314679

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  18 in total

1.  Posterior cortical atrophy: evidence for discrete syndromes of early-onset Alzheimer's disease.

Authors:  Po-Heng Tsai; Edmond Teng; Collin Liu; Mario F Mendez
Journal:  Am J Alzheimers Dis Other Demen       Date:  2011-08-09       Impact factor: 2.035

2.  Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.

Authors:  Rik Ossenkoppele; Niklas Mattsson; Charlotte E Teunissen; Frederik Barkhof; Yolande Pijnenburg; Philip Scheltens; Wiesje M van der Flier; Gil D Rabinovici
Journal:  Neurobiol Aging       Date:  2015-04-25       Impact factor: 4.673

3.  Distinct patterns of increased translocator protein in posterior cortical atrophy and amnestic Alzheimer's disease.

Authors:  William C Kreisl; Chul Hyoung Lyoo; Jeih-San Liow; Joseph Snow; Emily Page; Kimberly J Jenko; Cheryl L Morse; Sami S Zoghbi; Victor W Pike; R Scott Turner; Robert B Innis
Journal:  Neurobiol Aging       Date:  2016-12-16       Impact factor: 4.673

4.  Cerebrospinal fluid biomarkers in clinical subtypes of early-onset Alzheimer's disease.

Authors:  Edmond Teng; Tritia R Yamasaki; Michelle Tran; Julia J Hsiao; David L Sultzer; Mario F Mendez
Journal:  Dement Geriatr Cogn Disord       Date:  2013-12-31       Impact factor: 2.959

5.  Further evidence about the crucial role of CSF biomarkers in diagnosis of posterior cortical atrophy.

Authors:  E Coppi; L Ferrari; R Santangelo; F Caso; P Pinto; G Passerini; G Comi; G Magnani
Journal:  Neurol Sci       Date:  2014-02-02       Impact factor: 3.307

6.  Is AD a homogeneous nosologic entity? Yes.

Authors:  P Martinez-Martin
Journal:  J Neural Transm (Vienna)       Date:  2013-07-05       Impact factor: 3.575

7.  In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings.

Authors:  Maïté Formaglio; Nicolas Costes; Jérémie Seguin; Yannick Tholance; Didier Le Bars; Isabelle Roullet-Solignac; Bernadette Mercier; Pierre Krolak-Salmon; Alain Vighetto
Journal:  J Neurol       Date:  2011-04-10       Impact factor: 4.849

Review 8.  Dementia and neuroimaging.

Authors:  Federica Agosta; Francesca Caso; Massimo Filippi
Journal:  J Neurol       Date:  2012-12-15       Impact factor: 4.849

9.  Visual Ratings of Medial Temporal Lobe Atrophy Correlate with CSF Tau Indices in Clinical Variants of Early-Onset Alzheimer Disease.

Authors:  Elias Granadillo; Pongsatorn Paholpak; Mario F Mendez; Edmond Teng
Journal:  Dement Geriatr Cogn Disord       Date:  2017-07-05       Impact factor: 2.959

Review 10.  The paradox of syndromic diversity in Alzheimer disease.

Authors:  Jason D Warren; Phillip D Fletcher; Hannah L Golden
Journal:  Nat Rev Neurol       Date:  2012-07-17       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.